Aziz Moez Karim, Herrmann Joerg, Marmagkiolis Konstantinos, Balanescu Dinu Valentin, Donisan Teodora, Pushparaji Bala, Lin Heather Y, Tomakin Gerryross, Hoyt Taylor, Pham Martin, Dijkstra Jouke, Cilingiroglu Mehmet, Lopez-Mattei Juan, Zaha Vlad, Anderson H Vernon, Feldman Marc D, Molony Donald A, Iliescu Cezar A
Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
McGovern Medical School at The University of Texas Health Science Center at Houston, Houston, TX, United States.
Front Cardiovasc Med. 2021 Jun 7;8:665303. doi: 10.3389/fcvm.2021.665303. eCollection 2021.
This study assessed stent healing patterns and cardiovascular outcomes by optical coherence tomography (OCT) in cancer patients after drug-eluting stent (DES) placement. Cancer treatment, owing to its cytotoxic and antiproliferative effects, could delay stent healing and increase stent thrombosis risk, especially when dual antiplatelet therapy (DAPT) is discontinued early for oncological treatment. OCT can assess stent endothelialization and other healing parameters, which may provide clinical guidance in these challenging scenarios. This single-center retrospective study enrolled all cancer patients who underwent OCT for assessment of vascular healing patterns after prior DES placement from November 2009 to November 2018. Primary study endpoints were stent healing parameters, including stent coverage, apposition, degree of expansion, neointimal hyperplasia heterogeneity, in-stent restenosis, stent thrombosis, and overall survival (OS). A total of 67 patients were included in this study. Mean time between DES placement and OCT evaluation was 154 ± 82 days. Stent healing matched published values for DES in non-cancer patients ( ≥ 0.063). At 1 year, the OS was 86% (95% confidence interval [CI]: 78-96%) with 0% incidence of acute coronary syndrome. Advanced cancers and active chemotherapies were associated with inferior OS ( = 0.024, hazard ratio [HR]: 3.50, 95% CI: 1.18-10.42 and = 0.026, HR: 2.65, 95% CI: 1.13-6.22, respectively), while stent healing parameters were unassociated with OS. Forty-one patients (61%) had DAPT duration ≤6 months. Stent healing of contemporary DES appears similar in cancer and non-cancer patients. Cardiovascular risk of cancer patients after DES placement can be managed to facilitate timely cancer therapies, as the underlying malignancy and active chemotherapy ultimately determine survival.
本研究通过光学相干断层扫描(OCT)评估了癌症患者药物洗脱支架(DES)置入后的支架愈合模式和心血管结局。由于癌症治疗具有细胞毒性和抗增殖作用,可能会延迟支架愈合并增加支架血栓形成风险,尤其是在为进行肿瘤治疗而提前停用双联抗血小板治疗(DAPT)时。OCT可评估支架内皮化及其他愈合参数,这可能为这些具有挑战性的情况提供临床指导。这项单中心回顾性研究纳入了2009年11月至2018年11月期间所有接受过OCT以评估既往DES置入后血管愈合模式的癌症患者。主要研究终点为支架愈合参数,包括支架覆盖率、贴壁情况、扩张程度、新生内膜增生异质性、支架内再狭窄、支架血栓形成及总生存期(OS)。本研究共纳入67例患者。DES置入与OCT评估之间的平均时间为154±82天。支架愈合情况与非癌症患者DES的已发表值相符(≥0.063)。1年时,OS为86%(95%置信区间[CI]:78 - 96%),急性冠状动脉综合征发生率为0%。晚期癌症和积极的化疗与较差的OS相关(分别为P = 0.024,风险比[HR]:3.50,95%CI:1.18 - 10.42;P = 0.026,HR:2.65,95%CI:1.13 - 6.22),而支架愈合参数与OS无关。41例患者(61%)的DAPT持续时间≤6个月。当代DES在癌症患者和非癌症患者中的支架愈合情况似乎相似。DES置入后癌症患者的心血管风险可得到控制,以便及时进行癌症治疗,因为潜在的恶性肿瘤和积极的化疗最终决定生存情况。